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Abstract
Objective
To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and
1 year.
Methods
One hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation’s International
Clinical Outcome Study forDysferlinopathy. Baseline, 6-month, and 1-year assessments included adaptedNorth Star
Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test
(6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed
the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared
between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to
complete a 10-meter walk]) and clinical diagnosis.
Results
The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score
was the most sensitive test in the mild andmoderate groups, while the 6MWTwas most sensitive in the severe group.
The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In non-
ambulant patients, theMFMdomain 3, wrist flexion strength, and pinch gripweremost sensitive. Progression rates did
not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to
determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint.
Conclusion
Certain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and
potentially be useful in monitoring progression in clinical trials.
ClinicalTrials.gov identifier:
NCT01676077.
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Dysferlinopathy is a rare, recessively inherited muscular dys-
trophy caused by mutations in the DYSF1–4 gene. Potential
therapies are in development, and some of them have entered
human clinical trials (NCT02579239, NCT01863004,
NCT02710500). As the development of newly licensed and
emerging treatments for Duchenne muscular dystrophy5,6
and spinal muscular atrophy type 17 has shown, proving ef-
ficacy and satisfying regulators can be difficult in slowly pro-
gressive and varied conditions.8
Appropriate powering of a clinical trial requires understanding
of disease progression and responsiveness of various outcome
measures over time.9 Selection of outcomemeasures for clinical
trials in dysferlinopathy is particularly challenging. Dysferlin-
opathy is characterized by a range of ages at onset and patterns
of weakness and severity,4,10 variable rate of progression,4
modifying factors that are not clearly elucidated,10–13 and no
appropriate measures for monitoring progression. While some
measures such as the Motor Function Measure (MFM) have
been shown to be reliable in dysferlinopathy,14 the variability of
progression makes it difficult to demonstrate responsiveness in
small cohorts.
The Jain Clinical Outcome Study in Dysferlinopathy (COS)
aims to address these difficulties by characterizing the clinical,
biochemical, and radiologic parameters of 209 patients with
dysferlinopathy over 3 years.
This article summarizes findings from a planned interim
analysis of baseline, 6-month, and year 1 data to determine
whether disease progression is detectable and which measures
are most able to detect this progress. We propose a power
calculation using the most sensitive measures to determine
a potential clinical trial cohort required to demonstrate sig-
nificant functional change.
Methods
The COS study
The COS study is an international collaborative study of
patients with a genetic and/or protein assay–confirmed di-
agnosis of dysferlinopathy.4 Screening, baseline, 6-month, and
1-year visits took place between October 2012 and March
2016. One hundred ninety-seven of the original 209 recruited
patients completed a baseline visit. Of the original 209
patients, 7 did not meet inclusion criteria, and 5 chose not to
continue past the screening visit (figure 1). Full inclusion and
exclusion criteria, the study protocol, and patient de-
mographics have been described previously.4
Standard protocol approvals, registrations,
and patient consents
The study was initially approved by the following: NRES
Committee North East—Newcastle & North Tyneside on
February 2, 2012 (reference 211/NE/0360/R&D 5918). The
study was also approved by ethics review boards in each
country. All patients provided written informed consent. The
trial was registered at ClinicalTrials.gov (NCT01676077).
Functional outcome measures
Clinical assessments were standardized through trainings at
investigator meetings, and all evaluations were performed by
trained clinicians. Assessments included the adapted North
Star Ambulatory Assessment (a-NSAA),4 MFM-20, timed
function tests (timed rise from floor, 10-m walk/run, 4-stair
climb and descend, Timed Up and Go, and the 6-minute walk
test [6MWT]), Brooke Upper Extremity Scale, Jebsen Hand
Function Test, manual muscle testing (MMT), and hand-held
dynamometry (HHD). No assessments have been specifically
validated in a dysferlin-specific population. These assessments
were chosen because of their widespread suitability for limb
girdle muscular dystrophy. The MFM-20 was selected over
the MFM-32 to reduce patient fatigue and duplication. All
assessments were attempted for ambulant patients. Non-
ambulant patients did not complete the a-NSAA or
ambulation-based timed function tests.
Muscle strength was assessed with an 11-point scale for
MMT.4 The best of 3 attempts for HHDwas used for analysis.
Functional ability was assessed with qualitative scales and
timed tests. Total scores were calculated for the a-NSAA15 in
ambulant patients, and the MFM-20 and the Brooke scale
were calculated in all patients. TheMFM-20 was also analyzed
on the basis of its 3 components: D1 (standing and transfers),
D2 (axial and proximal), and D3 (distal). Any patient with an
incomplete score was excluded from analysis for that test. To
account for patients who became nonambulant or unable to
complete timed function tests due to disease progression,
timed test values were converted to velocity measures (either
meter per second or task per second), with a 0-m/s velocity
assigned for the first instance a patient was unable to complete
the test.
Patient perception of progression
The ACTIVLIM questionnaire, a Rasch-built patient-
reported outcome measure,16 was used to capture patient-
reported functional ability. The total score, out of a maximum
of 36, was compared between visits. A higher score indicates
greater functional ability.
Glossary
a-NSAA = adapted North Star Ambulatory Assessment;COS = Jain Clinical Outcome Study in Dysferlinopathy;HHD = hand-
held dynamometry; LGMD2B = limb girdle muscular dystrophy 2B;MFM =Motor FunctionMeasure;MMT =manual muscle
testing; 6MWT = 6-minute walk test; SRM = standardized response mean.
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Statistical analysis
Statistical analysis was completed with SAS 9.3 (SAS Institute
Inc, Cary, NC). Mean and median change scores were cal-
culated for each test between baseline and 6 months, 6
months and year 1, and baseline and year 1. Data from some
visits were excluded if the visit occurred ±2 months outside
the scheduled appointment date. A majority of functional
outcome measures were not normally distributed; thus,
comparisons between baseline and follow-up time points
were conducted with the Wilcoxon signed rank-sum test and
standardized response mean (SRM).17 A comparison was
made between the performance of patients with the most
common clinical diagnoses of limb girdle muscular dystrophy
2B (LGMD2B) and Miyoshi myopathy with Kruskal-Wallis
test with Steel-Dwass-Critchlow-Fligner correction for mul-
tiple comparisons.18
Nonambulant patients (unable to walk 10 meters with usual
orthotics and walking aids) were compared to 3 categories of
ambulant patients: ambulation affected severely, moderately,
or mildly. Using patients’ a-NSAA scores at baseline, we de-
fined ambulant severity categories based on a clinical im-
pression of disease severity and binomial distribution of
a-NSAA scores, with cut points of 0 to 10 (severe disease
severity), 11 to 40 (moderate disease severity), and 41+ (mild
disease severity). The lower cut point was based on the end of
the first a-NSAA peak, and the high cut point was placed at the
start of the second peak, with the wide spread in between
representing a plateau between peaks. Significance was de-
fined as p ≤ 0.05. Results are expressed as median change
(range) and p value.
Power analyses to support a hypothetical future clinical trial
were conducted to estimate the sample size required to detect
significant statistical differences in progression over the course
of 1 year with PASS 14 software. Because change scores were
normally distributed, calculations used mean change scores
and SDs of the functional measure that demonstrated most
change over time. For this analysis, the a-NSAA was used,
which limited estimates to ambulant patients only. Sample
sizes needed to evaluate a variety of expected drug effects were
calculated for reference, including halting of disease pro-
gression (i.e., assuming mean progression estimates from the
current sample among untreated and no progression among
treated patients), reflective of potential protein-restoring ge-
netic therapies. An α level of 0.05, 80% power, and a treated-
to-untreated ratio of 1:1 were assumed. For comparison with
a widely used measure in muscular dystrophy, sample sizes
were also calculated on the basis of the 6MWT.
Data availability statement
Deidentified cohort level data can be requested. All protocol
assessments are in the public domain apart from the a-NSAA,
which can be requested from the steering group (publication
in draft). The statistical plan is detailed above. All data for this
natural history study will be stored for at least 5 years after the
end of the study. Data can be requested by all interested
stakeholders for clinical research and trial planning. Data
requests are reviewed by the Jain COS Steering Committee,
who can be contacted via the corresponding author.
Results
Of the initial 197 eligible enrolled patients, 3 patients with-
drew after baseline, and 1 withdrew after 6 months. This is
summarized in figure 1. Patients included in this analysis were
between 11 and 86 years of age at baseline and were at all
stages of disease progression, from asymptomatic hyper-
CKemia to nonambulant.
Functional outcome measures
Functional outcome measure results are summarized in tables
1 and 2, figure 2, and table e-1 (available from Dryad, doi.org/
10.5061/dryad.tp08m60). Some of the assessments, by their
Figure 1 Flowchart of patient numbers at each visit
Number of patients who completed each assessment (baseline, 6 months, and 12 months) and how many of them were used for each analysis window.
Neurology.org/N Neurology | Volume 92, Number 5 | January 29, 2019 e3
Table 1 Change in scores of functional tests from baseline to 6 months, 6 months to 1 year, and baseline to 1 year for the a-NSAA, MFM, Jebsen, Brooke, patient-reported
ACTIVLIM, and 6-minute walk tests
Outcome measure
Baseline
median
score
Change in score, baseline–6 mo Change in score, 6 mo–1 y Change in score, baseline–1 y
SRMn Median (range) p Value n Median (range) p Value n
Median
(range) p Value
Total North Star scorea 19 130 −1.00 (−19.0 to 19.0) <0.0001a 119 0.00 (−14.0 to 5.00) 0.025a 117 −2.00 (−16.0 to 7.00) <0.0001b 0.61
Total MFM scorea 45 161 −1.00 (−17.0 to 7.00) <0.0001a 148 −0.50 (−11.0 to 11.0) 0.0226a 149 −1.00 (−13.0 to 6.00) <0.0001b 0.44
MFM D1 scorea 10 166 0.00 (−7.00 to 4.00) 0.0007a 152 0.00 (−7.00 to 6.00) 0.0033a 151 −1.00 (−8.00 to 6.00) <0.0001b 0.4
MFM D2 scorec 23 166 0.00 (−12.0 to 5.00) 0.0004c 154 0.00 (−6.00 to 10.0) 0.7945 157 0.00 (−8.00 to 5.00) 0.0171b 0.19
MFM D3 scoreb 11 174 0.00 (−3.00 to 2.00) 0.0655 158 0.00 (−3.00 to 3.00) 0.1431 160 0.00 (−6.00 to 2.00) 0.0011b 0.26
Brooke Upper Extremity Scaleb 1 181 0.00 (−2.00 to 5.00) 0.2025 164 0.00 (−5.00 to 2.00) 0.477 164 0.00 (−2.00 to 2.00) 0.0334b 0.18
ACTIVLIM total scorea 26 180 0.00 (−9.00 to 8.00) 0.0042a 165 0.00 (−9.00 to 10.0) 0.0026a 164 −1.00 (−8.00 to 6.00) <0.0001b 0.46
Jebsen writing time taken, s 12.7 180 0.10 (−17.3 to 14.9) 0.5794 165 0.10 (−11.3 to 30.5) 0.56 162 −0.15 (−14.4 to 28.1) 0.7109 0.11
6-min walk distance, meters/minc 331 124 −4.00 (−95.0 to 123) 0.2041 112 −7.00 (−110 to 51.0) 0.0003c 113 −13.0 (−123 to 142) <0.0001b 0.37
Abbreviations: a-NSAA = adapted North Star Ambulatory Assessment; MFM = Motor Function Measure; SLM = standardized response mean.
p Values were calculated with the Wilcoxon signed-rank method. The SRM is a measure of effect size reported for change over 1 year.
a Consistent significant change over 6 months.
b Change over 1 year.
c Change over one 6-month period but not both 6-month periods.
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Table 2 Change scores for MMT with a possible range of scores of 0 to 10 and HHM measured with a dynamometer
Median score
at baseline,
median (range)
Change in score, baseline–6 mo Change in score, 6 mo–1 year Change in score, baseline–1 y
SRMn Median (range) p Value n Median (range) p Value n Median (range) p Value
MMT shoulder flexion 7 (1–10) 184 0.00 (−3.00 to 3.00) 0.9973 169 0.00 (−3.00 to 3.00) 0.0577 166 0.00 (−4.00 to 3.00) 0.1979 0.20
MMT shoulder abductiona 7 (1–10) 184 0.00 (−6.00 to 5.00) 0.2465 169 0.00 (−4.00 to 4.00) 0.1172 166 0.00 (−4.00 to 3.00) 0.011a 0.11
HHM elbow flexion biceps, lbb 16.60 (1.00–65.00) 177 −0.70 (−24.5 to 10.80) 0.0012b 159 −0.20 (−28.7 to 16.90) 0.9424 156 −0.60 (−30.6 to 15.10) 0.0026a 0.23
MMT elbow flexion bicepsb 8 (1–10) 184 0.00 (−4.00 to 4.00) 0.0322b 169 0.00 (−4.00 to 4.00) 0.1412 166 0.00 (−4.00 to 4.00) 0.0016a 0.13
HHM elbow flexion brachioradialis, lb 16.40 (0.00–56.60) 175 −0.30 (−29.1 to 17.80) 0.1451 159 −0.10 (−20.4 to 14.40) 0.5082 156 −0.45 (−32.9 to 15.20) 0.0616 0.07
MMT elbow flexion brachioradialis 8 (1–10) 184 0.00 (−5.00 to 3.00) 0.7979 169 0.00 (−4.00 to 4.00) 0.1109 166 0.00 (−5.00 to 3.00) 0.1388 0.24
MMT elbow extensiona 8.00 (2–10) 176 0.00 (−5.00 to 4.00) 0.1263 161 0.00 (−3.00 to 5.00) 0.9587 160 0.00 (−5.00 to 4.00) 0.0472a 0.03
MMT wrist flexiona 9 (2–10) 184 0.00 (−7.00 to 5.00) 0.0647 169 0.00 (−8.00 to 6.00) 0.3377 166 0.00 (−4.00 to 3.00) 0.0024a 0.15
HHM wrist flexion, lb 15.80 (0.00–46.10) 176 0.00 (−18.1 to 15.10) 0.721 161 −0.20 (−22.4 to 17.30) 0.4597 158 −0.15 (−28.3 to 15.30) 0.8098 0.04
HHM wrist extension, lb 20.40 (3.10–50.30) 178 −0.15 (−16.3 to 20.30) 0.5521 163 0.00 (−25.0 to 15.40) 0.9028 160 −0.55 (−26.9 to 17.60) 0.162 0.23
MMT wrist extension 9 (3–10) 184 0.00 (−3.00 to 4.00) 0.4453 169 0.00 (−3.00 to 4.00) 0.5773 166 0.00 (−3.00 to 3.00) 0.3273 0.16
HHM grip, lbb 60.00 (0.00–260.0) 172 −1.00 (−173 to 103.1) 0.1287 160 −1.00 (−83.0 to 94.40) 0.0058b 152 −2.00 (−186 to 94.90) 0.0004a 0.01
HHM pinch grip, lbb 24.80 (0.00–97.00) 171 0.00 (−42.0 to 39.00) 0.2784 158 −1.00 (−35.0 to 22.00) <0.0001b 150 −1.00 (−34.0 to 40.00) 0.0019a 0.20
MMT hip flexiona 6 (0–10) 176 0.00 (−7.00 to 4.00) 0.3953 160 0.00 (−4.00 to 7.00) 0.1663 160 0.00 (−5.00 to 4.00) 0.0093a 0.18
MMT hip extension 3 (0–10) 173 0.00 (−4.00 to 5.00) 0.5764 156 0.00 (−4.00 to 5.00) 0.9785 155 0.00 (−7.00 to 4.00) 0.6247 0.04
MMT hip abduction 6 (1–10) 175 0.00 (−5.00 to 7.00) 0.2452 156 0.00 (−5.00 to 5.00) 0.5303 156 0.00 (−7.00 to 7.00) 0.5382 0.26
HHM hip abduction, lb 20.50 (2.10–71.80) 161 0.10 (−37.4 to 34.30) 0.4108 148 0.10 (−33.3 to 22.70) 0.6222 149 0.10 (−36.5 to 26.10) 0.49 0.21
MMT hip adductionb 2 (0–10) 175 0.00 (−5.00 to 5.00) 0.0732 156 0.00 (−4.00 to 4.00) 0.0052b 156 0.00 (−5.00 to 5.00) 0.0009a 0.16
HHM hip adduction, lba 11.65 (0.00–49.60) 147 −0.10 (−25.2 to 21.30) 0.5118 133 −0.40 (−22.4 to 15.30) 0.0838 138 −1.15 (−28.4 to 17.20) 0.0168a
MMT knee flexionb 4 (0–10) 173 0.00 (−5.00 to 4.00) 0.0256b 155 0.00 (−3.00 to 4.00) 0.6457 155 0.00 (−5.00 to 3.00) 0.014a 0.26
HHM knee flexion, lbb 9.60 (0.00–65.70) 141 −0.70 (−19.0 to 15.90) 0.007b 127 −0.40 (−34.1 to 14.80) 0.1201 127 −1.20 (−44.5 to 20.00) <0.0001a 0.20
MMT knee extension 3 (0–10) 182 0.00 (−3.00 to 4.00) 0.5574 167 0.00 (−4.00 to 5.00) 0.2943 164 0.00 (−5.00 to 5.00) 0.5064 0.12
HHM knee extension, lbb 11.80 (0.00–95.30) 154 −0.55 (−35.2 to 22.60) 0.0007b 139 −0.20 (−39.5 to 41.10) 0.3253 138 −0.80 (−37.7 to 19.70) 0.0052a 0.05
MMT ankle dorsiflexiona 4 (0–10) 180 0.00 (−7.00 to 6.00) 0.1944 165 0.00 (−6.00 to 7.00) 0.1841 164 0.00 (−5.00 to 6.00) 0.0295a 0.24
HHM ankle dorsiflexion, lbb 11.30 (0.00–55.90) 140 −0.75 (−29.5 to 22.70) 0.0018b 118 0.00 (−28.8 to 30.00) 0.7194 118 −0.50 (−40.5 to 25.90) 0.0537 0.23
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nature, are suitable only for ambulant patients. In addition,
some patients did not complete all assessments because of
equipment or individual patient factors such as recent injury
and were excluded from analysis of that assessment. The
number of patients who completed each assessment is listed.
The a-NSAA, MFM-20 (total and subdomain D1), the Timed
Up and Go, and timed 10-meter walk showed significant
change in median score over both 6-month periods and 1 year
(table 1 and figure 2); no MMT or HHD values changed
consistently over both 6-month windows (table 2).
The MFM D2, some MMT and HHD, velocity to rise from
floor, climb 4 stairs, descend 4 stairs, and the 6MWT showed
significant change over only one 6-month window and over 1
year (tables 1 and 2 and figure 2).
The MFM D3, some MMT and HHD, and the Brooke scale
showed change in median score at 1 year but did not change
over either 6-month windows (tables 1 and 2).
The timed test demonstrating the greatest change in velocity
was the 10-meter walk, changing −0.1 m/s (range −1.24 to
0.55 m/s) from a baseline median velocity of 1.11 m/s (range
0.00–4.55 m/s). The velocity of all timed tests at year 1
slowed by almost 10% of baseline velocity for that task
(figure 2).
The Jebsen Hand Function Test and remaining MMT and
HHD tests showed no change over 1 year.
The tests most responsive to change for the whole cohort, as
calculated by the SRM, were NSAA (SRM 0.61), 10-meter
walk/run velocity (0.56), ACTIVLIM (0.46), rise from floor
velocity (0.44), and MFM total score (0.44).
When assessed by severity subgroup, for ambulant patients,
the a-NSAA was the most sensitive test in the mildly (SRM
0.44) and moderately (SRM 0.89) affected groups, while the
6MWT was most sensitive in the severely affected ambulant
group (SRM 0.9). The 10-meter walk was the only test
showing significant change in all ambulant subgroups. For
nonambulant patients, the most sensitive test was the MMT
for wrist flexion (SRM 0.69), while the most sensitive com-
bined measure was the distal domain of the MFM (SRM
0.46). Table e-1 (available from Dryad doi.org/10.5061/
dryad.tp08m60) shows SRM values for all assessments by
severity subgroup. Change in functional test scores (MFM
and a-NSAA) did not differ between the 2 most common
clinical diagnoses of LGMD2B and Miyoshi myopathy
(table 3).
Patient perception of progression
Responses recorded by the ACTIVLIM questionnaire sup-
ported the deterioration in function, with the ACTIVLIM
score decreasing statistically significantly over both 6 and 12
months (table 1).Ta
b
le
2
C
h
an
ge
sc
o
re
s
fo
r
M
M
T
w
it
h
a
p
o
ss
ib
le
ra
n
ge
o
f
sc
o
re
s
o
f
0
to
10
an
d
H
H
M
m
ea
su
re
d
w
it
h
a
d
yn
am
o
m
et
er
(c
on
tin
ue
d)
M
e
d
ia
n
sc
o
re
a
t
b
a
se
li
n
e
,
m
e
d
ia
n
(r
a
n
ge
)
C
h
a
n
ge
in
sc
o
re
,b
a
se
li
n
e
–
6
m
o
C
h
a
n
ge
in
sc
o
re
,6
m
o
–
1
ye
a
r
C
h
a
n
ge
in
sc
o
re
,b
a
se
li
n
e
–
1
y
SR
M
n
M
e
d
ia
n
(r
a
n
ge
)
p
V
a
lu
e
n
M
e
d
ia
n
(r
a
n
ge
)
p
V
a
lu
e
n
M
e
d
ia
n
(r
a
n
ge
)
p
V
a
lu
e
M
M
T
a
n
k
le
p
la
n
ta
rf
le
xi
o
n
(k
n
e
e
st
ra
ig
h
t)
a
3
(0
–
10
)
15
7
0.
00
(−
10
.0
to
7.
00
)
0.
27
3
13
9
0.
00
(−
6.
00
to
8.
00
)
0.
21
2
13
7
0.
00
(−
10
.0
to
8.
00
)
0.
01
93
a
0.
23
H
H
M
a
n
k
le
p
la
n
ta
r
fl
e
xo
rs
(k
n
e
e
st
ra
ig
h
t)
,l
b
12
.6
0
(0
.0
0–
81
.0
0)
14
0
−
0.
40
(−
34
.2
to
23
.7
0)
0.
21
12
7
−
0.
50
(−
28
.6
to
32
.9
0)
0.
22
9
12
3
−
0.
70
(−
33
.9
to
30
.2
0)
0.
19
45
0.
23
M
M
T
a
n
k
le
p
la
n
ta
rf
le
xi
o
n
(k
n
e
e
fl
e
xe
d
)a
3
(0
–
10
)
17
3
0.
00
(−
6.
00
to
7.
00
)
0.
25
28
15
4
0.
00
(−
5.
00
to
6.
00
)
0.
24
2
15
3
0.
00
(−
6.
00
to
5.
00
)
0.
01
74
a
0.
04
H
H
M
a
n
k
le
p
la
n
ta
r
fl
e
xo
rs
(k
n
e
e
fl
e
xe
d
),
lb
b
12
.2
0
(0
.0
0–
57
.9
0)
14
4
−
0.
75
(−
25
.6
to
29
.0
0)
0.
01
38
b
12
7
−
0.
30
(−
34
.5
to
22
.1
0)
0.
22
34
12
4
−
1.
15
(−
39
.6
to
22
.6
0)
0.
00
2a
0.
17
M
M
T
a
n
k
le
in
ve
rs
io
n
7
(0
–
10
)
18
0
0.
00
(−
7.
00
to
6.
00
)
0.
68
28
16
5
0.
00
(−
5.
00
to
4.
00
)
0.
81
54
16
4
0.
00
(−
4.
00
to
5.
00
)
0.
67
89
0.
16
M
M
T
a
n
k
le
e
ve
rs
io
n
b
5
(0
–
10
)
17
9
0.
00
(−
6.
00
to
4.
00
)
0.
82
32
16
4
0.
00
(−
5.
00
to
4.
00
)
0.
00
03
b
16
4
0.
00
(−
6.
00
to
3.
00
)
0.
01
3a
0.
21
A
b
b
re
vi
at
io
n
s:
H
H
M
=
h
an
d
-h
el
d
m
yo
m
et
ry
;M
M
T
=
m
an
u
al
m
u
sc
le
te
st
in
g;
SR
M
=
st
an
d
ar
d
iz
ed
re
sp
o
n
se
m
ea
n
.
W
h
en
th
e
sa
m
e
m
u
sc
le
gr
o
u
p
s
ar
e
te
st
ed
b
y
b
o
th
m
et
h
o
d
s,
th
ey
ar
e
gr
o
u
p
ed
to
ge
th
er
to
ai
d
in
te
rp
re
ta
ti
o
n
.p
V
al
u
es
w
er
e
ca
lc
u
la
te
d
w
it
h
th
e
W
ilc
o
xo
n
si
gn
ed
-r
an
k
m
et
h
o
d
.N
o
M
M
T
o
r
H
H
M
as
se
ss
m
en
ts
ch
an
ge
d
co
n
si
st
en
tl
y
o
ve
r
b
o
th
6-
m
o
n
th
p
er
io
d
s.
Th
e
SR
M
,a
m
ea
su
re
o
f
ef
fe
ct
si
ze
,i
s
re
p
o
rt
ed
fo
r
ch
an
ge
o
ve
r
1
ye
ar
.M
M
T
an
d
H
H
M
as
se
ss
m
en
ts
al
ls
h
o
w
ed
lo
w
re
sp
o
n
si
ve
n
es
s
to
ch
an
ge
.
a
C
h
an
ge
o
ve
r
1
ye
ar
.
b
C
h
an
ge
o
ve
r
a
si
n
gl
e
6-
m
o
n
th
p
er
io
d
b
u
t
n
o
t
b
o
th
6-
m
o
n
th
p
er
io
d
s.
e6 Neurology | Volume 92, Number 5 | January 29, 2019 Neurology.org/N
Estimated sample size for trials
Estimated clinical trial sample size is highly dependent on the
expected treatment effect; the smaller the effect size, the larger
the sample required (table 4). For example, with the inclusion
of ambulant patients of all disease severities, a total of 328
patients (164 in both the treatment and placebo groups)
would be needed to detect a 50% reduction in disease pro-
gression (i.e., half the deterioration seen in the current sam-
ple) over 1 year compared to 90 patients (45 in each group)
needed to detect halting in progression. The a-NSAA was
chosen for its capability to detect change as demonstrated by
the highest overall SRM in the current analysis. Limiting
a clinical trial to a subset of patients in the moderate severity
group at baseline, who showed the greatest changes in
a-NSAA scores over 1 year, would reduce the total sample size
to 176 for a 50% reduction in progression and 46 to detect
a halt in progression. A treatment that is anticipated to im-
prove muscle function, producing a greater effect size than
simply halting progression, would require even fewer patients.
The 6MWT would require 216 ambulant patients to detect
a halting of progression. However, as reflected by the high
SRM in the severe-ambulant population, if trials were limited
to the severe-ambulant subgroup of patients, 42 patients
would be needed to detect a halting in progression with the
6MWT.
Figure 2 Change in timed tests over 6 months and 1 year
Boxplots showing range, interquartile
range (IQR), and median values of time
taken to perform timed tests. Paired com-
parisons of calculated velocity (1/time in
seconds) were used to determine signifi-
cant vs insignificant change in order to in-
clude those unable to complete the test.
These are displayed as time taken to com-
plete each task (rather than velocity) to aid
visual interpretation. Comparisons of
baseline and year 1, baseline and 6
months, and 6 months and 1 year are
shown. The numbers differ depending on
the number of patients completing each
test at both visits. Blue shows significant
change (p < 0.05) over 1 year; red shows if
change is seen over both 6-month periods;
and green shows change in only the green
6-month window. Some patients were very
slow, and those taking >25 seconds to
complete a test are not displayed but are
included in median and IQR calculations.
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Table 3 Scores in LGMD2B and Miyoshi myopathy
Outcome
LGMD2B Miyoshi myopathy
Kruskal-
Wallis
test of
difference
between
groups
n
Median
(range) p Value SRM n
Median
(range)
p
Value SRM p Value
Total North Star score 67 −2.00 (−14.0 to 5.00) <0.0001 0.69 35 −2.00 (−16.0 to 7.00) 0.0015 0.50 0.8663
Total MFM Score 84 −1.00 (−13.0 to 6.00) <0.0001 0.46 48 −1.00 (−10.0 to 6.00) 0.0131 0.38 0.87
MFM D1 score 85 −1.00 (−6.00 to 6.00) 0.0006 0.36 49 0.00 (−8.00 to 3.00) 0.0042 0.42 0.8898
MFM D2 score 91 0.00 (−8.00 to 4.00) 0.0201 0.25 49 0.00 (−4.00 to 5.00) 0.4588 0.08 0.8873
MFM D3 score 92 0.00 (−3.00 to 2.00) 0.0026 0.32 51 0.00 (−6.00 to 2.00) 0.2350 0.19 0.6595
MMT shoulder abduction 97 0.00 (−4.00 to 3.00) 0.0530 0.21 51 0.00 (−2.00 to 2.00) 0.2754 0.18 0.9883
MMT shoulder flexion 97 0.00 (−3.00 to 2.00) 0.2873 0.12 51 0.00 (−2.00 to 3.00) 0.8111 0.02 0.8958
MMT elbow flexion biceps 97 0.00 (−4.00 to 4.00) 0.1284 0.16 51 0.00 (−3.00 to 3.00) 0.0505 0.25 0.9713
MMT elbow flexion
brachioradialis
97 0.00 (−5.00 to 3.00) 0.3926 0.11 51 0.00 (−3.00 to 3.00) 0.7598 0.03 0.9249
MMT wrist extension 97 0.00 (−3.00 to 3.00) 0.9115 0.01 51 0.00 (−2.00 to 2.00) 0.6209 0.09 0.8412
MMT wrist flexion 97 0.00 (−4.00 to 3.00) 0.0750 0.19 51 0.00 (−4.00 to 3.00) 0.0444 0.28 0.9326
MMT knee extension 96 0.00 (−3.00 to 4.00) 0.9472 0.04 51 0.00 (−3.00 to 5.00) 0.5997 0.06 0.9994
MMT ankle dorsiflexion 96 0.00 (−5.00 to 4.00) 0.0536 0.20 51 0.00 (−3.00 to 6.00) 0.1403 0.14 0.9966
MMT ankle inversion 96 0.00 (−4.00 to 4.00) 0.8853 0.01 51 0.00 (−4.00 to 5.00) 0.7866 0.04 0.9927
MMT ankle eversion 96 0.00 (−5.00 to 3.00) 0.0701 0.22 51 0.00 (−6.00 to 3.00) 0.1469 0.22 0.9941
MMT ankle plantarflexion
(knee straight)a
78 0.00 (−5.00 to 8.00) 0.6160 0.02 44 0.00 (−10.0 to 7.00) 0.0062 0.36 0.0455
MMT ankle plantarflexion
(knee flexed)
86 0.00 (−6.00 to 5.00) 0.2716 0.11 50 0.00 (−2.00 to 5.00) 0.0876 0.17 0.6968
MMT hip extension 88 0.00 (−5.00 to 4.00) 0.2450 0.12 50 0.00 (−7.00 to 2.00) 0.4626 0.37 0.423
MMT knee flexion 89 0.00 (−5.00 to 3.00) 0.3173 0.14 50 0.00 (−3.00 to 2.00) 0.0147 0.20 0.3917
MMT hip Abduction 89 0.00 (−7.00 to 7.00) 0.2638 0.12 50 0.00 (−4.00 to 6.00) 0.5599 0.10 0.4836
MMT hip Adduction 89 0.00 (−5.00 to 3.00) 0.0025 0.32 50 0.00 (−5.00 to 5.00) 0.6168 0.06 0.2017
MMT hip flexion 92 0.00 (−5.00 to 2.00) 0.1230 0.19 51 0.00 (−3.00 to 4.00) 0.1110 0.20 0.8431
MMT elbow extension 92 0.00 (−5.00 to 4.00) 0.0653 0.20 51 0.00 (−3.00 to 4.00) 0.8632 0.02 0.6868
HHM elbow flexion biceps, lb 91 −0.30 (−17.6 to 11.00) 0.0904 0.24 48 −0.85 (−23.6 to 15.10) 0.0498 0.23 0.7967
HHM elbow flexion
brachioradialis, lb
91 −0.60 (−20.5 to 8.20) 0.2003 0.19 48 0.20 (−21.0 to 15.20) 0.5768 0.09 0.9248
HHM wrist extension, lba 93 −1.40 (−17.4 to 14.60) 0.0173 0.21 50 1.40 (−15.5 to 17.60) 0.0798 0.15 0.0187
HHM wrist flexion, lb 93 −0.10 (−16.6 to 15.30) 0.8544 0.03 48 0.60 (−10.4 to 7.60) 0.5540 0.05 0.8952
HHM grip, lb 93 −1.00 (−186 to 87.10) 0.0085 0.27 42 −2.00 (−85.0 to 62.90) 0.1015 0.25 0.9728
HHM pinch grip, lb 93 −1.00 (−31.0 to 40.00) 0.0175 0.19 42 0.00 (−27.0 to 16.00) 0.2026 0.28 0.9623
HHM knee extension, lb 81 −0.10 (−30.3 to 15.50) 0.2259 0.17 42 −1.10 (−36.6 to 19.70) 0.0215 0.24 0.5599
HHM knee flexion, lb 73 −1.00 (−11.6 to 16.60) 0.0276 0.14 39 −1.00 (−13.5 to 20.00) 0.0011 0.21 0.6533
HHM hip abduction, lb 86 −0.10 (−14.7 to 19.20) 0.8929 0.08 48 0.90 (−36.5 to 26.10) 0.0948 0.11 0.3955
Continued
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Discussion
This analysis supports the use of specified physical and patient-
reported outcome measures in the assessment of dysferlinop-
athy by demonstrating clinically detectable deterioration in
muscle strength and function and self-reported deterioration
over 6 months and 1 year in a large cohort of patients.
Defining a set of disease specific tests is useful in coordinating
further research and patient follow-up and developing clinical
trial outcome measures. The most sensitive assessments for
monitoring progression in dysferlinopathy that were identified
in this study are the a-NSAA, MFM-20, timed 10-meter walk,
and Timed Up and Go; they demonstrated consistent change
over both 6 months and 1 year with a relatively high SRM.
Other tests such as the Brooke and some MMT assessments
showed change over 1 year but not 6 months, suggesting that
they are less sensitive scales. This was also true for D3 (distal
function) of the MFM, consistent with other published cross-
sectional data on its poor suitability for this population.14 Some
tests such as the 6MWT and MFM D2 domain changed over
one 6-month window but not the other. This poor repeatability
of demonstrable change makes these measures less reliable in
assessing the dysferlinopathy patient cohort as a whole.
The 6MWT showed the highest SRM for the severely affected
ambulant patients, perhaps capturing a large deterioration in
the walking pace of some of these weak patients as they lose
ambulation. However, this is unlikely to be used in clinical
trials, particularly because this subgroup of patients is small
(37 severe-ambulant patients in this study), thus reducing the
number of patients available to appropriately power a study.
Trials in rare diseases are often forced to rely on small cohort
sizes. Here, we show that while variation in physical progression
can be high in dysferlinopathy, sensitive outcome measures can
be identified (a-NSAA, 10-meter walk, etc.), particularly in
ambulant patients. We confirm that a moderate disease severity
group based on the a-NSAA could be identified, making it
possible to power a clinical trial with a reasonably sized sample.
The actual number needed would depend on the expected
treatment effect over 1 year. Numbers needed for a trial could
be further reduced by using this longitudinal natural history
sample as a control group for future clinical studies.19 In addi-
tion, longer evaluation times and identification ofmore sensitive
scoring systems could further reduce the number of participants
needed for effective clinical trials. Future work aiming to assess
the cohort by modeling methods will look at progression based
on a variety of disease and environmental factors to attempt to
determine whether any subgroups exist with differing rates of
progression. Any particularly fast-progressing group would be
very good candidates for potential trials in terms of both patient
benefit and reduced sample size requirement.
Increasing the sensitivity and utility of functional scoring
systems across the disease spectrum requires the creation of
Table 3 Scores in LGMD2B and Miyoshi myopathy (continued)
Outcome
LGMD2B Miyoshi myopathy
Kruskal-
Wallis
test of
difference
between
groups
n
Median
(range) p Value SRM n
Median
(range)
p
Value SRM p Value
HHM hip adduction, lb 82 −1.00 (−20.8 to 13.40) 0.1396 0.16 41 −1.10 (−15.5 to 17.20) 0.2555 0.07 0.9905
HHM ankle dorsiflexion, lb 68 −0.65 (−18.5 to 17.00) 0.0833 0.15 35 0.00 (−22.2 to 25.90) 0.8751 0.01 0.5334
HHM ankle plantar flexors (knee
flexed), lb
71 −1.00 (−23.0 to 20.90) 0.0331 0.24 37 −1.20 (−10.7 to 16.10) 0.1155 0.11 0.9482
HHM ankle plantar flexors (knee
straight), lb
71 −1.00 (−27.0 to 17.30) 0.1283 0.18 36 −0.45 (−30.6 to 14.40) 0.9234 0.08 0.69
Brooke Upper Extremity Scale 97 0.00 (−1.00 to 2.00) 0.0301 0.21 51 0.00 (−1.00 to 1.00) 0.3877 0.17 0.9764
ACTIVLIM total score 95 −1.00 (−8.00 to 4.00) <0.0001 0.51 51 −1.00 (−8.00 to 6.00) 0.0520 0.28 0.8076
Jebsen writing time taken, s 95 −0.20 (−14.4 to 28.10) 0.6479 0.15 49 0.50 (−10.5 to 6.40) 0.5693 0.04 0.9795
6-min walk test total distance,
meters/min
65 −8.00 (−123 to 71.00) 0.0137 0.33 34 −15.50 (−108 to 142.0) 0.0607 0.24 0.9881
Abbreviations: HHM = hand-held myometry; LGMD2B = limb girdle muscular dystrophy type 2B; MFM = Motor Function Measure; MMT = manual muscle
testing; SRM = standardized response mean.
This table shows the change scores over 1 year for patientswith a diagnosis of LGMD2BorMiyoshimyopathy. Change scoreswere comparedbetween groups
with the Kruskal-Wallis test and Steel-Dwass-Critchlow-Fligner control for multiple comparisons. The SRM is a measure of effect size demonstrated by each
test, shown for each diagnostic group. Overall functional scores of the MFM and adapted North Star Ambulatory Assessment did not differ between
diagnostic subgroups.
a Only 2 muscle groups (ankle plantar flexion and wrist extension) showed a difference between these 2 groups.
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a disease-specific scale. We are working to streamline the
a-NSAA andMFM-20 to remove redundant and less sensitive
items and to combine elements of each scale using a Rasch
analysis20 to create a linearizable, dysferlin-specific score. This
modified scale, called the North Star Assessment for Dysfer-
linopathy, will be validated with the 2- and 3-year COS visits
and will be assessed with Rasch analysis to determine whether
the new scale is capable of measuring change over a wider
proportion of the patient population over time.
Characterizing which individual muscles demonstrate most
rapid deterioration in dysferlinopathy is useful for both
monitoring progression and targeting potential therapeutics,
some of which involve local intramuscular injections.21 These
results over 1 year show some sensitivity to change of a few
distal muscle groups in nonambulant patients, in whom
functional scores are less useful. However, in ambulant
patients, there is a low responsiveness and high variability of
MMT and HHD results because measures of specific muscle
change. Other measures of strength, longer time scales, and
MRI may be needed to monitor effects of local treatments.
In all tests, a small number of individuals of all ages and disease
severities improved their time or qualitative functional score
over 1 year. While in some this may reflect a true improvement
in function, we would not expect an improvement in un-
derlying pathology. Therefore, it is likely that some of this
improvement can be attributed to potentially confounding
factors. With functional scales, improvement may be due to
a learning effect22; that is, patients become more practiced at
certain tests, although we attempted to mitigate this by having
all patients perform a full assessment at screening. Some
intertester variation in scoring is also possible because, although
all were trained by the same provider, different physiotherapists
conducted consecutive patient visits at some sites. However, we
anticipate this effect to be small because the functional
assessments used have previously demonstrated high inter-
tester reliability in other diseases,23–25 and intraclass correlation
comparison of baseline and screening results (table 5) shows
consistency of scoring, particularly for the a-NSAA (intraclass
correlation 0.99), on which much of this analysis is based.
Finally, this may simply reflect environmental, physiologic, or
individual factors such asmotivation or fatigue, which can cause
natural fluctuations in performance on functional tests22 on the
background of more slowly progressing pathology. If trends in
scores are maintained in future visits, suggesting a true sub-
group of static or even functionally improving patients, this will
be revisited to assess for potential disease modifiers.
The ACTIVLIM is a rating scale with documented high
sensitivity in many neuromuscular conditions.16,26 We have
shown that this holds true for the dysferlinopathy population,
who show changes in score across all levels of function. A very
small number of patients reported an improvement in the
ability to perform tasks of daily living. These patients had
undertaken lifestyle changes, including weight loss, dietary
change, and participation in physiotherapy. Future work will
explore and capture patient access to physiotherapy,
Table 4 Sample size estimates for a placebo-controlled clinical trial
Target study population
Target treatment effect, n
50% Reduction in
progression
75% Reduction in
progression
Halting of
progression
20%
Improvement
50%
Improvement
All ambulant patients 328 148 90 62 42
Moderate patients only (baseline
a-NSAA score 11–40)
176 80 46 34 22
Abbreviation: a-NSAA = adapted North Star Ambulatory Assessment.
Sample size estimates for a placebo-controlled clinical trial are based on projected mean change in a-NSAA score for variable treatment effects over 1 year.
The numbers represent the total sample size based on equally sized treatment and control groups. Calculations are based on an observed decrease in NSAA
score in untreated patients of 2.4 overall and 3.8 amongmoderate patients, the expected control effect. Estimated change in a-NSAA score among treatment
groups over 1 year is therefore as follows: 50% reduction, decrease of 1.2 (all) and 1.9 (moderate) in a-NSAA score; 75% reduction, decrease of 0.6 (all) and 0.9
(moderate) in a-NSAA score; halting of progression, no change in a-NSAA score; 20% improvement, increase of 0.5 (all) and 0.7 (moderate) in a-NSAA score;
and 50% improvement, increase of 1.2 (all) and 1.9 (moderate) in a-NSAA score.
Table 5 Intraclass correlation coefficient between
screening and baseline assessments for
functional tests carried out at a maximum of 90
days apart
Test Intraclass correlation n Multiple
NSAA 0.99 132 119
MFM total score 0.99 170 150
Time to stand 0.85 91 77
Time to walk/run 10 m 0.99 127 114
Timed Up and Go 0.84 112 104
Time to climb 4 steps 0.93 109 101
Time to descend 4 steps 0.53 108 101
6-min walk distance 0.97 129 121
ACTIVLIM 0.97 174 167
Abbreviations: MFM = Motor Function Measure; NSAA = North Star Ambu-
latory Assessment.
A high intraclass correlation demonstrates consistency between screening
and baseline assessments.
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participation in exercise, and the use of aids and adaptations in
the home and workplace. These findings suggest that the
ACTIVLIM is a reliable patient-reported outcome measure in
dysferlinopathy that is a valuable complementary tool for
clinical trials at any stage of the disease.
There are several limitations of this study. The first is the
relatively short period of time over which change was ex-
amined; this will be addressed in future analysis of this
3-year study. Second, the use of ordinal, rather than con-
tinuous, functional scales presented challenges in data
analysis, necessitating the use of medians, making intuitive
interpretation more difficult. However, these scales also
have benefits because a single point change on a functional
change necessarily represents a clinically, rather than sim-
ply statistically, noticeable change. Future work will explore
the potential to linearize these Rasch-based measures,
allowing us to keep the benefits of these scales while pro-
viding the opportunity to subject them to more rigorous
parametric statistics.
Although function is measured, the importance attributed by
patients to the loss of ability to perform 1 particular action
over another is not measured here. To clarify the clinical
significance of the statistically significant changes demon-
strated here, further correlations are needed between these
functional and patient-reported measures, as well as consid-
eration of patient valuation of the importance of the loss of
individual functions.
Our current assessment of arm function is limited in the
scales currently used in this study. Further work is required
to develop or determine suitable measures for upper limb
function.
This study demonstrates significant population-level change
over 6 months and 1 year in several functional and patient-
reported measures. We anticipate that the planned combi-
nation of the most sensitive elements of the a-NSAA and
MFM to create a dysferlin-specific score will produce an im-
portant measure that will become the basis for assessment of
progression in dysferlinopathy regardless of ambulatory sta-
tus. This measure combined with MRI data and further pa-
tient subgroup analysis will add to the pathophysiologic
understanding and trial readiness of the dysferlinopathy
population and may further reduce the cohort size required to
power potential clinical trials.
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